• / Free eNewsletters & Magazine
  • / My Account
Home>Pluristem stock rises 2.5% on mid-stage clinical trial results

Pluristem stock rises 2.5% on mid-stage clinical trial results

3party Content

Thu, 27 Jul 2017

Pluristem Therapeutics Inc. (PSTI) shares surged 2.5% to $1.21 in extremely heavy afternoon trade Wednesday after the company released new data from a clinical trial. The results, from a phase 2-equivalent clinical trial, focused on 12 primates and found that those primates had faster recovery in

©2017 Morningstar Advisor. All right reserved.